A new partnership with M42 is bringing specialist expertise in memory, cognitive and brain health to patients in Dubai and Al Ain, providing access to advanced assessment, diagnosis and treatment closer to home.
Re:Cognition Health has partnered with M42’s Mubadala Health Dubai (MHD) and Tawam Molecular Imaging Centre (TMIC) to expand access to specialist brain and mind health services across the UAE.
Marking Re:Cognition Health’s first clinical presence in the Middle East, the partnership brings more than 15 years of specialist experience to the region. The first phase has launched at Mubadala Health Dubai, with a second phase planned at Tawam Molecular Imaging Centre in Al Ain.
Bringing specialist brain health expertise closer to patients
The service will initially focus on memory concerns, cognitive impairment, Alzheimer’s disease and other neurodegenerative conditions, bringing together specialist clinical expertise and advanced diagnostic capabilities.
Re:Cognition Health’s multidisciplinary teams draw on expertise across neurology, neuroradiology, neuropsychology and psychiatry, supporting patients from initial consultation and assessment through to diagnosis, treatment planning and ongoing care.
Dr Moza Ajaif Al Zaabi, CEO of Mubadala Health Dubai, highlights the importance of improving access to coordinated specialist care:
“People experiencing changes in memory or cognition need timely answers and a clear route to appropriate care. Through this collaboration, we are bringing specialist assessment, diagnostics and treatment planning together within MHD’s multidisciplinary setting. This will help patients and families access coordinated care closer to home and give referring physicians a clearer pathway to specialist support.”
A comprehensive approach to diagnosis and treatment
Accurately identifying the cause of memory or cognitive changes may require a combination of clinical assessment, cognitive testing and advanced investigations.
Following an initial specialist consultation, further investigations may include:
- Blood tests to investigate potential contributors to cognitive symptoms.
- Magnetic resonance imaging (MRI) to assess brain structure and identify relevant changes.
- Amyloid PET imaging to identify amyloid protein deposits associated with Alzheimer’s disease.
- Cerebrospinal fluid analysis to investigate biomarkers associated with neurodegenerative conditions.
- Genetic testing, where appropriate, to help inform clinical assessment and care planning.
These investigations help clinicians build a clearer understanding of each patient’s condition and develop an individualised care plan based on their diagnosis, medical history and specific needs.
Tawam Molecular Imaging Centre’s advanced imaging capabilities will play an important role in supporting this diagnostic pathway. Dr Laila Abdelwareth, CEO of TMIC, explains:
“TMIC’s molecular imaging capabilities will play an important role in supporting accurate diagnosis and treatment planning for patients in Al Ain and the wider Abu Dhabi region. By connecting these capabilities with MHD’s clinical infrastructure and Re:Cognition Health’s specialist expertise, we are building a more connected model of memory and brain health care across the UAE.”
Expanding access to Alzheimer’s disease treatments
Advances in Alzheimer’s research have created new possibilities for people in the early stages of the disease. Disease-modifying therapies represent an important development, targeting underlying disease processes rather than simply managing symptoms.
For eligible patients with early Alzheimer’s disease, the service may provide access to these treatments, subject to clinical assessment, regulatory requirements and established eligibility criteria. Treatment requires careful patient selection, specialist oversight and appropriate safety monitoring.
Re:Cognition Health has extensive experience in Alzheimer’s clinical research, including international clinical trials investigating emerging disease-modifying treatments. This expertise informs its commitment to evidence-based diagnosis and patient care.
Expanding access to ADHD and autism services
The partnership will also broaden access to specialist services for neurodevelopmental conditions, including ADHD and autism.
Drawing on Re:Cognition Health’s established expertise in neurodevelopmental assessment and care, services will be introduced in phases, initially through telemedicine consultations in Dubai. This will provide individuals and families with access to specialist guidance and support for conditions that can affect cognition, behaviour, learning and everyday life.
A new chapter for specialist brain and mind healthcare
Dr Emer MacSweeney, CEO and Co-Founder of Re:Cognition Health, said:
“We are incredibly excited to be expanding Re:Cognition Health’s presence into the UAE in collaboration with Tawam Molecular Imaging Centre and M42’s Mubadala Health Dubai. This Brain & Mind Centre allows us to share our international experience and expertise in brain and mind health with patients across the region. By bringing together internationally recognised specialists, cutting-edge neuroscience and truly personalised medicine, we can deliver a more holistic approach to brain health. Our focus is on prevention, earlier diagnosis and more effective treatment, helping patients achieve the best possible brain and mind health throughout their lifetime.”
The partnership represents an important step in expanding access to specialist cognitive healthcare across the UAE, combining international clinical expertise with established local healthcare infrastructure.
Through its collaboration with M42, Re:Cognition Health aims to support earlier diagnosis, improve access to evidence-based treatments and provide specialist guidance for individuals and families navigating brain and mind health conditions.
